Actively Recruiting

Age: 18Years +
All Genders
NCT05880641

Use of Shockwave M5+/L6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access

Led by EndoCore Lab s.r.l. · Updated on 2026-03-25

40

Participants Needed

6

Research Sites

218 weeks

Total Duration

On this page

Sponsors

E

EndoCore Lab s.r.l.

Lead Sponsor

F

Fondazione Italiana Vascolare

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study will evaluate, in a controlled setting, the efficacy and safety of the intravascular lithotripsy using Shockwave™ M5+/L6 Peripheral Intravascular Lithotripsy Catheter to facilitate delivery of aortic large-bore devices in iliac calcified access.

CONDITIONS

Official Title

Use of Shockwave M5+/L6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Patient or legal representative understands the procedure and provides written consent before joining
  • Aortic disease requiring endovascular treatment with severely calcified iliac access making the procedure difficult
  • Ratio greater than 0.2 between the outer diameter of the aortic stent graft delivery system and the minimum lumen diameter
  • Calcium grade 3 or 4 based on 360° coronary classification
  • Lesion length greater than 20 mm, summing all calcified iliac lesions from aortic bifurcation to proximal common femoral artery
  • Eligible for treatment with Shockwave M5+ IVL device
  • Aortic disease indicated for endovascular treatment with or without aorto-iliac occlusive disease (Rutherford score II - VI for chronic limb ischemia)
  • Able to comply with follow-up visits as scheduled
Not Eligible

You will not qualify if you...

  • Bilateral iliac artery occlusion
  • Urgent condition with iliac thrombus causing acute limb ischemia
  • Hemodynamically unstable at the start of the procedure
  • Refusal of treatment
  • Contraindications to antiplatelet therapy, anticoagulants, or thrombolytic drugs
  • History of life-threatening reaction to contrast medium
  • Life expectancy less than twelve months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Azienda Ospedaliero Universitaria delle Marche

Ancona, Ancona, Italy, 60126

Actively Recruiting

2

Sant'Orsola Hospital

Bologna, Emilia-Romagna, Italy, 40138

Not Yet Recruiting

3

Fondazione PTV - Policlinico Tor Vergata

Rome, Lazio, Italy, 00133

Actively Recruiting

4

Ospedale San Giovanni di Dio

Florence, Tuscany, Italy, 50143

Not Yet Recruiting

5

Ospedale Santa Maria della Misericordia di Perugia

Perugia, Umbria, Italy, 06156

Not Yet Recruiting

6

Azienda Ospedaliero-Universitaria di Padova

Padova, Veneto, Italy, 35128

Not Yet Recruiting

Loading map...

Research Team

D

Daniela Ramaccini, PhD, PharmD

CONTACT

S

Stefano Fazzini, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here